Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdKCNH2-G628S Gene Therapy for Post-Operative Atrial Fibrillation
NCT05223725Phase 1Withdrawn
- Sponsor
- University of Massachusetts
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AdKCNH2-G628S in Atrial fibrillation (AFib), sponsored by University of Massachusetts. Planned start Oct 2023; status: withdrawn.
02
Drugs
AdKCNH2-G628S
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05223725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223725.